Men's Health News

RSS

The Lancet journal publishes XGEVA Phase 3 study results against prostate cancer, bone metastases

Amgen today announced the publication of results from a Phase 3 head-to-head trial that compared XGEVA to Zometa in preventing bone complications called skeletal-related events in 1,901 men with prostate cancer and bone metastases.

25 Feb 2011

Variation in PSA levels does not predict prostate cancer, may lead to unnecessary biopsies

Researchers at Memorial Sloan-Kettering Cancer Center have found that change in PSA levels over time — known as PSA velocity — is a poor predictor of prostate cancer and may lead to many unnecessary biopsies.

25 Feb 2011

Focused Ultrasound Surgery Foundation releases men's heath update on prostate cancer, BPH treatments

The Focused Ultrasound Surgery Foundation has released a special men's heath update in its February 2011 online newsletter.

23 Feb 2011

Study: Cannabis use may negatively impact male sexual performance

Rany Shamloul's recent review of the medical literature on cannabis use and sexual health has revealed that cannabis use may negatively impact male sexual performance.

23 Feb 2011

CDC maps least and most active Americans

A new government commissioned study has found that Colorado has one of the most active populations in the country and Kentucky has one of the least active. This study is the third in a series of county-focused reports by the federal Centers for Disease Control and Prevention (CDC). The first two looked at diabetes and obesity rates, says Ann Albright, director of the CDC’s Division of Diabetes Translation.

20 Feb 2011

Jenny Craig to launch new male-targeted weight loss initiative

Jenny Craig, Inc., one of the leading authorities on weight management, is launching a new male-targeted initiative titled "Jen Works for Men" with celebrity spokesperson Jason Alexander as the face of the new campaign. Alexander, who famously lost 30 pounds on the program, wrote, directed and starred in the new series of national commercials for the weight loss company, slated to launch on Monday, February 21, 2011.

19 Feb 2011

Phase I/II safety, efficacy data for Bellicum's BPX-101 presented at 2011 Genitourinary Cancers Symposium

Bellicum Pharmaceuticals, Inc. today announced the presentation of Phase I/II safety and efficacy data for BPX-101, a novel drug-activated dendritic cell vaccine for metastatic castrate resistant prostate cancer (mCRPC), in three separate posters at the 2011 Genitourinary Cancers Symposium held in Orlando, Florida on February 17 – 19, 2011.

19 Feb 2011

Positive interim data from cabozantinib Phase 2 metastatic castration-resistant prostate cancer trial

Exelixis, Inc. today reported updated interim data from the cohort of patients with metastatic castration-resistant prostate cancer (CRPC) treated with cabozantinib (XL184) in an ongoing phase 2 adaptive randomized discontinuation trial.

18 Feb 2011

Skeleton regulates fertility in males, but not females

Researchers at Columbia University Medical Center have discovered that the skeleton acts as a regulator of fertility in male mice through a hormone released by bone, known as osteocalcin.

17 Feb 2011

Genomic Health to present prostate cancer studies at ASCO Genitourinary Cancer Symposium

Genomic Health, Inc. today announced the presentation of two studies at the American Society of Clinical Oncology® (ASCO®) Genitourinary (GU) Cancer Symposium, including complete results from its prostate cancer gene identification study, which identified 295 genes strongly associated with clinical recurrence following radical prostatectomy with great consistency across multiple tumor samples examined in each patient.

17 Feb 2011

Early balding linked to prostate cancer: Study

Balding early in life causes grief for many men and now new research will cause even more alarm. Researchers have found that early balding may be liked to prostate cancer.

16 Feb 2011

Men going bald at young age more likely to develop prostate cancer in later life

Men who start to lose hair at the age of 20 are more likely to develop prostate cancer in later life and might benefit from screening for the disease, according to a new study published online in the cancer journal, Annals of Oncology today.

15 Feb 2011

Apricus Bio awards Neopharm exclusive rights to market and sell Vitaros in Israel and Palestinian Territories

Apricus Biosciences, Inc., announced today that it has entered into a licensing agreement granting Neopharm Group the exclusive rights to market and sell Vitaros®, Apricus Bio's treatment for erectile dysfunction ("ED") and, when and if available, its formulation for the treatment of premature ejaculation ("PE"), in Israel and the Palestinian Territories of the Gaza Strip and the West Bank.

15 Feb 2011

Vitamin D levels not linked to prostate cancer development

Vitamin D levels do not affect men's chances of developing prostate cancer, according to new research published in the journal Cancer Causes and Control.

14 Feb 2011

Sequencing of whole prostate cancer genomes - an historic development

Today's announcement regarding the sequencing of whole prostate cancer genomes is an historic development in the fight against prostate cancer. The ability to sequence whole genomes will spare some patients from unnecessary treatments and side effects while eliminating an estimated $1.5 billion that is spent each year on overtreatment. The complete research findings will be published in the February 10 issue of Nature.

14 Feb 2011

Genetic map for prostate cancer

Researchers have managed to uncover the whole genetic sequence in prostate cancer. This complete map, hope researchers, will eventually lead to the development of more targeted drugs and a better understanding of which prostate cancers are likely to spread, one of the biggest challenges for physicians and patients.

13 Feb 2011

Genes for prostate cancer mapped for the first time

A genetic blue print that uncovers many of the mutations and genetic damage that drives prostate cancer and could lead to new treatments and better diagnosis has been found. This would mean earlier detection and new breeds of drugs to reverse the damage. Also each patient could have his own “cancer chart” made so that his treatment is personalized. The study, conducted by researchers from the Broad Institute, Dana-Farber Cancer Institute and Weill Cornell Medical College, appears in the Feb. 10 issue of Nature.

13 Feb 2011

Perrigo to settle patent litigation relating to Minoxidil foam

Perrigo Company today announced that it has agreed to settle its Hatch-Waxman litigation relating to Minoxidil foam brought by Stiefel Research Australia Pty. Ltd., a GSK Company. Under the terms of the settlement, Perrigo can launch in the U. S., a generic version of Men's Rogaine® Foam on March 1, 2012, or earlier under certain circumstances.

11 Feb 2011

Genta initiates new Phase 2 clinical trial of tesetaxel in patients with advanced prostate cancer

Genta Incorporated today announced that the Company has initiated a new Phase 2 clinical trial of tesetaxel in patients with advanced prostate cancer. Tesetaxel, the leading oral taxane in clinical development, will be evaluated for its use as both first- and second-line chemotherapy.

10 Feb 2011

Full genetic blueprint of multiple prostate tumors laid bare

For the first time, researchers have laid bare the full genetic blueprint of multiple prostate tumors, uncovering alterations that have never before been detected and offering a deep view of the genetic missteps that underlie the disease. The study, made possible by key advances in whole genome sequencing and analysis, points to several new prostate cancer genes and a critical category of genomic changes as important drivers of prostate cancer growth.